Feature Story  

Merck, Pfizer combo treatment boosts kidney cancer survival

Mon, Feb 11, 2019
Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.
  Newsifi

New York, New York

Email : info@newsifi.com